Prestige Biopharma, a biopharmaceutical company focused on antibody therapeutics, announced an exclusive license and supply agreement with Biosidus, a biotechnology company based in Buenos Aires, Argentina, to commercialize Tuznue (trastuzumab) across Latin America, including Argentina, Mexico, Bolivia, and Paraguay. Tuznue is a biosimilar to Herceptin approved for treating breast cancer and metastatic gastric cancer. The European Commission granted marketing authorization for Tuznue in September 2024, representing a significant milestone for Prestige Biopharma’s biosimilar portfolio and supporting broader access to cost-effective treatments in key global markets.
Health Technology Insights: Ryder and BJC Win Award for Healthcare Supply Chain Innovation
Under the terms of the agreement, Biosidus will have exclusive rights to market and distribute Tuznue in the designated countries, leveraging its established commercial network and experience in biosimilar adoption. Prestige Biopharma will produce and supply the drug substance from its EU-GMP-certified, high-tech facility, while Biosidus will manufacture the final drug product at its Buenos Aires site, distributing it locally in Argentina and exporting to Mexico, Paraguay, and Bolivia.
Health Technology Insights: Merck Reports Positive Phase 3 Results for DOR/ISL HIV Therapy
Lisa S. Park, CEO of Prestige Biopharma, stated that the partnership with Biosidus reflects a strategic collaboration to ensure successful commercialization in Latin America. She emphasized that Biosidus’ regional expertise and proven track record make it an ideal partner for launching Tuznue, and that the partnership will strengthen the global reach and value of Prestige Biopharma’s biosimilar portfolio.
Mariano Elizalde, CEO of Biosidus, highlighted the significance of the agreement in expanding access to biotechnological medicines in the region. He noted that introducing Tuznue will enhance Biosidus’ biosimilar portfolio while providing patients and healthcare professionals with a high-quality and affordable treatment option.
The collaboration combines Prestige Biopharma’s advanced manufacturing capabilities with Biosidus’ regional knowledge and distribution network, aiming to accelerate patient access to Tuznue across key Latin American markets and support sustainable growth for both companies’ biosimilar programs.
Health Technology Insights: Medscape Launches AI-Powered Medical Intelligence for HCPs
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
